Showing results (1-10 of 273) with videos related to
Sort By:
Pageof 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2011
Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotypeCarmine Carbone, Tania Moccia, Cihui Zhu, et al.Journal of the National Cancer Institute|July 12, 2011
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1Davide Melisi, Qianghua Xia, Genni Paradiso, et al.Frontiers in Oncology|May 12, 2020
Permissive State of EMT: The Role of Immune Cell CompartmentVita Fedele, Davide MelisiExpert Opinion on Therapeutic Targets|March 27, 2012
NF-κB as a target for pancreatic cancer therapyCarmine Carbone, Davide MelisiInternational Journal of Molecular Sciences|November 20, 2020
New Prognostic and Predictive Markers in Cancer ProgressionSusan Costantini, Alfredo BudillonExpert Opinion on Therapeutic Targets|January 18, 2007
NF-kappa B as a target for cancer therapyDavide Melisi, Paul J ChiaoCancers|September 13, 2017
EMT and Treatment Resistance in Pancreatic CancerNicola Gaianigo, Davide Melisi, Carmine CarboneFuture Oncology (London, England)|October 9, 2020
Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinomaValeria Merz, Camilla Zecchetto, Davide MelisiCancer Treatment Reviews|March 26, 2026
Targeted therapeutic strategies in rare subtypes of pancreatic cancer: Histology, molecular profiles, and emerging opportunitiesEnza Scarlato, Nelson Dusetti, Davide MelisiCurrent Pharmaceutical Design|February 3, 2004
Angiogenesis: a target for cancer therapyGiampaolo Tortora, Davide Melisi, Fortunato CiardielloPageof 28